These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 27632203)

  • 21. Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting.
    Burmeister H; Aebi S; Studer C; Fey MF; Gautschi O
    Support Care Cancer; 2012 Jan; 20(1):141-7. PubMed ID: 21234609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan.
    Tamura K; Aiba K; Saeki T; Nakanishi Y; Kamura T; Baba H; Yoshida K; Yamamoto N; Kitagawa Y; Maehara Y; Shimokawa M; Hirata K; Kitajima M;
    Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation.
    Hayashi T; Ikesue H; Esaki T; Fukazawa M; Abe M; Ohno S; Tomizawa T; Oishi R
    Support Care Cancer; 2012 Aug; 20(8):1805-10. PubMed ID: 21947491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Ruhlmann CH; Jahn F; Schwartzberg L; Rapoport B; Rittenberg CN; Clark-Snow R
    Support Care Cancer; 2017 Jan; 25(1):297-301. PubMed ID: 27572335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
    De Tursi M; Carella C; Tomao S; Cinieri S; Lorusso V; Marchetti P; Vecchio S; Sansoni E; Contu A; Adamo V; Silvestris N; Nuzzo A; Rosti G; Ravaioli A; Danova M; Tonini G; Passalacqua R; Cruciani G; Faedi M; Spada M; De Laurentiis M; Amoroso D; Tomao F; Sperduti I; Grassadonia A; Tinari N; Natoli C; Iacobelli S;
    Tumori; 2014; 100(6):e309-13. PubMed ID: 25688518
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association Between Medical Marijuana Cardholder Status and Antiemetic Overuse.
    Baltz AP; Peng C; Gressler L; Bhatti S; Lewis K
    Cannabis Cannabinoid Res; 2024 Oct; ():. PubMed ID: 39419579
    [No Abstract]   [Full Text] [Related]  

  • 27. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Italian Group for Antiemetic Research.
    Ann Oncol; 1998 Jul; 9(7):759-65. PubMed ID: 9739443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiemetic effectiveness and nausea and vomiting incidence during capecitabine and oxaliplatin chemotherapy.
    Chan A; Tan SH; Low XH; Yap KY
    Nurs Res; 2012; 61(6):405-12. PubMed ID: 22960588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
    Koch S; Wein A; Siebler J; Boxberger F; Neurath MF; Harich HD; Hohenberger W; Dörje F
    Support Care Cancer; 2013 Sep; 21(9):2395-402. PubMed ID: 23568765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis.
    Patel P; Paw Cho Sing E; Dupuis LL
    Expert Opin Drug Saf; 2019 Feb; 18(2):97-110. PubMed ID: 30640557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.
    Hesketh PJ; Gandara DR; Hesketh AM; Facada A; Perez EA; Webber LM; Martin LA; Cramer MB; Hahne WF
    Support Care Cancer; 1996 Mar; 4(2):141-6. PubMed ID: 8673351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran.
    Nikbakht Z; Rajabi M; Shahrasbi A; Roohi E; Hashemian F
    J Cancer Educ; 2021 Oct; 36(5):1022-1029. PubMed ID: 31955393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.
    Olver I; Clark-Snow RA; Ballatori E; Espersen BT; Bria E; Jordan K
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S33-6. PubMed ID: 20803222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Cost-utility Analysis Between Aprepitant- and Fosaprepitant-containing Regimens To Prevent Chemotherapy-induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy in Japan.
    Kashiwa M; Matsushita R
    Clin Ther; 2019 May; 41(5):929-942. PubMed ID: 31036286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art.
    Grunberg SM; Warr D; Gralla RJ; Rapoport BL; Hesketh PJ; Jordan K; Espersen BT
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S43-7. PubMed ID: 20972805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
    Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
    Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain.
    Escobar Álvarez Y; De Castro Carpeño J; Bell D; Drago A; Franceschetti A
    Clin Transl Oncol; 2021 Oct; 23(10):2155-2162. PubMed ID: 33956310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.